Home Infusion - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The home infusion market size in 2026 is estimated at USD 27.58 billion, growing from 2025 value of USD 25.99 billion with 2031 projections showing USD 37.12 billion, growing at 6.12% CAGR over 2026-2031. This report is Segmented by Product (Infusion Pump Sets {Large-Volume, Syringe, and More}, Accessories and More), Applications (Anti-Infective Therapy, Parenteral Nutrition (TPN), and More), End User (Hom Ame-Care Settings, Hospital Out-Patient Departments, and More), and Geography (North America, Europe, Asia-Pacific, More). The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Home Infusion Market Trends and Insights

Aging Population and Chronic-Disease Burden Population

Aging reshapes care-delivery priorities, with the United Nations projecting the global 65-plus cohort to reach 1.6 billion by 2050. Two-thirds of these seniors will live in Asia, intensifying demand for chronic-disease therapies that can be administered outside hospitals. In Europe, new cancer cases climbed to 3.2 million in 2022, while treatment spending doubled to EUR 146 billion in 2023. The clinical load drives sustained uptake of portable and elastomeric pumps that support immunotherapy, parenteral nutrition, and long-term antibiotic regimens. Stakeholders view precise home delivery as a counterbalance to hospital bed shortages and budget pressures, solidifying the growth outlook for the home infusion market.

Uptake of Home Care to Cut Hospital Costs

Payers increasingly reward home-based delivery because it trims facility overhead, shortens inpatient stays, and improves patient satisfaction. The 2025 home health update raised Medicare reimbursement for home health agencies by 2.7%, reinforcing the economics of shifting infusion services away from hospitals. COVID-19 accelerated this migration, and specialty infusion expenditures grew 38% in 2023, a trend projected to continue as high-cost cell and gene therapies enter commercial rollout. Private-equity investment mirrors these incentives; Court Square Capital Partners’ stake in Soleo Health underlines financial confidence in scalable home infusion platforms. As health systems rationalize site-of-care mix, infusion providers that demonstrate outcomes equivalence at lower total cost gain preferred-network status.

High Acquisition and Maintenance Cost of Infusion Pumps

Advanced pumps blend mechanical precision with complex software, raising up-front capital needs and ongoing service fees. Smaller operators struggle to fund the latest smart models, encouraging partnership with third-party engineering firms such as Prescott’s, which Morgan Stanley Capital Partners acquired to improve device uptime across provider sites. Regulatory demands for cybersecurity patches and firmware validation add recurring expense that only scaled enterprises can absorb readily. Consequently, cost hurdles slow technology, refresh rates in emerging markets and intensify consolidation pressure in mature geographies.

Other drivers and restraints analyzed in the detailed report include:

• Expansion Of Medicare Home-Infusion Benefit
• Private-Equity Funding Surge for Ambulatory Infusion Centers
• Device-related Adverse Events and Recalls

Segment Analysis

Infusion pumps captured 49.60% of 2025 revenue, cementing their role as the backbone of home dosing accuracy. Portable models, favored for their compact designs and intuitive interfaces, are projected to log an 10.7% CAGR to 2031. The home infusion market size for portable pumps is therefore set to expand far faster than legacy large-volume models, which still serve patients discharged with high-flow hydration or nutrition needs. Elastomeric pumps, which operate without external power, earn physician support in outpatient antimicrobial therapy thanks to proven cost savings of EUR 4,031 per episode when refill programs are deployed. Smart connectivity functions further differentiate premium units by enabling clinicians to adjust parameters remotely and create audit trails that satisfy payer audits. Consumables such as IV sets and antimicrobial filters ride the installed-base wave, yielding recurring revenue streams that buttress manufacturers' financial models.

Growth momentum ripples across adjunct categories as well. Patient-controlled analgesia units improve post-operative recovery at home by aligning opioid dosing with real-time pain scores, thereby reducing hospital readmissions. Insulin patch pumps combine continuous glucose sensing with closed-loop algorithms; early data show improved glycemic control yet adoption lags due to device cost and patient-training requirements. Software updates remain a regulatory flashpoint: the April 2025 FDA warning to ICU Medical exemplifies the compliance expectations that manufacturers must meet when enhancing user interfaces or wireless protocols. Overall, product innovation anchors revenue growth, reinforcing the competitive weight of firms that can integrate electromechanical reliability with cloud analytics.

Complete Report Scope:

• By Product
  • Infusion Pumps
    • Large-volume pumps
    • Syringe pumps
    • Elastomeric pumps
    • Insulin pumps
    • Patient-controlled analgesia (PCA) pumps
  • IV Administration Sets
  • Accessories & Disposables
• By Application
  • Anti-infective Therapy
  • Parenteral Nutrition (TPN)
  • Chemotherapy/Oncology
  • Hydration Therapy
  • Pain & Analgesia Management
  • Endocrinology
  • Other Applications
• By End User
  • Home-care Settings
  • Ambulatory Infusion Centers
  • Hospital Out-patient Departments
  • Specialty Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commands 51.85% of global revenue, powered by Medicare’s robust home infusion benefit and a dense web of accredited suppliers. The United States alone could redirect up to USD 265 billion of facility spend to home settings by 2025, according to policy analysts, giving the home infusion market size unparalleled expansion leeway. Canada’s provincial systems adopt similar care-migration strategies, while Mexico’s private insurers introduce bundled home-infusion packages to court its growing middle class. Device manufacturers prioritize UL-listed products and cybersecurity features to align with stringent FDA and Health Canada requirements, which in turn nurture clinician confidence.

Asia-Pacific exhibits the fastest regional CAGR at 8.74% through 2031. Rapid population aging, rising chronic-disease prevalence, and infrastructure investments under the Asian Infrastructure Investment Bank's health strategy form a potent triad of growth drivers. China’s Healthy China 2030 policy elevates home-based chronic-care modalities, creating an addressable market that attracts both local pump makers and multinationals. Japan, already a super-aged society, expands its long-term insurance program to subsidize infusion equipment rentals, while South Korea pioneers AI-enabled pump oversight through nationwide 5G networks. In South and Southeast Asia, pharmaceutical production clusters in India and Singapore localize supply chains, trimming import duties and shortening lead times.

Europe presents heterogeneity in reimbursement but benefits from the European Medicines Agency’s centralized drug approvals. Germany and France implement national home-infusion formularies under social-insurance umbrellas; the United Kingdom’s National Health Service pilots “out-of-hospital chemotherapy” that leverages local nursing agencies. Southern and Eastern European countries lag due to budget constraints, though EU regional funds occasionally subsidize digital-health adoption.

The Middle East and Africa remain nascent yet promising. Gulf Cooperation Council nations, led by Saudi Arabia and the United Arab Emirates, invest in smart-hospital and home-care ecosystems powered by high broadband penetration. Sub-Saharan Africa sees sporadic pilot programs for HIV and tuberculosis home therapy, but infrastructure deficits and reimbursement gaps limit scale. In South America, Brazil and Argentina spearhead adoption, driven by demographic shifts and expanding private insurance. Currency volatility, however, raises equipment prices, necessitating creative financing solutions such as vendor leasing and outcome-based contracts.

List of Companies Covered in this Report:

• Baxter
• B. Braun
• Fresenius
• ICU Medical
• Smiths Group
• Option Care Health
• Coram CVS Health
• UnitedHealth/Optum Infusion
• Terumo Corp.
• Medtronic
• Moog Medical
• Nipro Corp.
• Beckton Dickinson
• CareFusion (BD)
• Apria Healthcare
• Aveanna Healthcare
• InfuSystem Holdings
• KabaFusion

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support